Moderna's study indicates that a new combination vaccine for flu and COVID-19 generates a stronger immune response in older adults compared to existing standalone vaccines. The shots use mRNA technology, which is proven in other vaccines, but health regulators want additional data, particularly regarding effectiveness against infection. Although promising, experts are skeptical about public acceptance and the logistical challenges posed by the seasonal nature of flu and the persistent presence of COVID-19. Moderna has filed for approval, postponing its target to 2026 due to FDA requests for further efficacy data.
Researchers from vaccine-maker Moderna reported that a new combination shot for flu and COVID-19 generated a stronger immune response than existing standalone shots.
The mRNA technology, which has been pivotal for COVID-19 vaccines, shows promise for flu shots but hasn't been approved for that use yet.
Collection
[
|
...
]